A similar mechanism of STAT3 activation by nuclear CD133 may also be responsible for increased tumor progression in endometrial cancer, since STAT3 was previously shown to be activated in human endometrial cancers and inhibition of its signaling was suggested to be an effective target for cancer treatment [29]. The gene discussed is PROM1; the disease is cancer.